BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 12516287)

  • 1. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects].
    Peces R; Olea T
    Nefrologia; 2002; 22(6):540-6. PubMed ID: 12516287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features of and recent advances in therapy for Fabry disease.
    Brady RO; Schiffmann R
    JAMA; 2000 Dec; 284(21):2771-5. PubMed ID: 11105184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical spectrum of Anderson Fabry disease in a Romanian family.
    Tudor A; Muşat A; Doscan A; Bari M; Zapucioiu C; Urdea E; Cochior D; Peţa D
    Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabry disease: molecular genetics of the inherited nephropathy.
    Desnick RJ; Astrin KH; Bishop DF
    Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of patients with Fabry disease in Argentina].
    AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
    Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations].
    Germain DP
    J Soc Biol; 2002; 196(2):183-90. PubMed ID: 12360747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney transplantation and enzyme alpha-galactosidase A therapy in patient with Fabry disease: a case report.
    Dziemianko I; Jezior D; Boratyńska M; Patrzałek D; Kuźniar J; Szyber P; Klinger M
    Transplant Proc; 2007 Nov; 39(9):2925-7. PubMed ID: 18022018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fabry disease: treatment and diagnosis.
    Rozenfeld PA
    IUBMB Life; 2009 Nov; 61(11):1043-50. PubMed ID: 19859978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fabry's disease; towards a treatment].
    Linthorst GE; Hollak CE; Bosman DK; Heymans HS; Aerts JM
    Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2391-5. PubMed ID: 11145093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F; Wanner C
    J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
    Desnick RJ; Banikazemi M
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anderson-Fabry disease].
    Kes P; Basić-Jukić N; Brunetta B; Jurić I
    Acta Med Croatica; 2006; 60(1):55-8. PubMed ID: 16802573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal involvement in Anderson-Fabry disease.
    Sessa A; Meroni M; Battini G; Righetti M; Maglio A; Tosoni A; Nebuloni M; Vago G; Giordano F
    J Nephrol; 2003; 16(2):310-3. PubMed ID: 12774774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
    Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
    J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease manifestations and X inactivation in heterozygous females with Fabry disease.
    Maier EM; Osterrieder S; Whybra C; Ries M; Gal A; Beck M; Roscher AA; Muntau AC
    Acta Paediatr Suppl; 2006 Apr; 95(451):30-8. PubMed ID: 16720462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of multiple angiomas without any angiokeratomas in a female heterozygote with Fabry disease.
    Mirceva V; Hein R; Ring J; Möhrenschlager M
    Australas J Dermatol; 2010 Feb; 51(1):36-8. PubMed ID: 20148840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Two cases of heterozygous Fabry disease].
    Shibuya Y; Oku N; Suzuki Y; Gomi T
    Nihon Jinzo Gakkai Shi; 2006; 48(5):421-7. PubMed ID: 16913464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fabry disease in patients with end-stage renal failure: the potential benefits of screening.
    Bekri S; Enica A; Ghafari T; Plaza G; Champenois I; Choukroun G; Unwin R; Jaeger P
    Nephron Clin Pract; 2005; 101(1):c33-8. PubMed ID: 15886492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients.
    Navarro C; Teijeira S; Dominguez C; Fernandez JM; Rivas E; Fachal C; Barrera S; Rodriguez C; Iranzo P
    Acta Neuropathol; 2006 Feb; 111(2):178-85. PubMed ID: 16463201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.